

Important Update About Ophthalmic Drug (Avastin) for Medicare Advantage Providers

Florida Blue is aware of a product discontinuation initiated by Pine Pharmaceuticals that could impact the supply of compounded bevacizumab (Avastin®) for ophthalmic use.

Summary of Facility's Product Discontinuation

Pine Pharmaceuticals is one of the facilities that has produced compounded bevacizumab for ophthalmic use. On October 11, 2024, Pine Pharmaceuticals announced it stopped production of compounded bevacizumab for ophthalmic use after an inspection by the U.S. Food and Drug Administration (FDA). The inspection led to concerns related to product sterility and quality control issues.

Alternate Sources

There are two other 503B compounding facilities, Fagron Sterile Services, LLC and Leiters Health, approved to prepare ophthalmic bevacizumab. Providers have the option to obtain bevacizumab from these suppliers. If you are unable to acquire the medication from an alternate source, you can request a medical necessity review for another medication.

To learn more about the compounded product recall, please visit the FDA website at [FDA.gov](https://www.fda.gov).